QDIS Blog

A blog about chemistry, drug development, science, and technology

Pages (999999): [1] 2 3 » ... Last »

September 12, 2006

New Threat from TB

by @ 1:36 pm.  Filed under Health News

Tuberculosis (TB) has been making a come back for a long time. Although it has been practically wiped out in the Western world it is still fairly prevalent in other parts of the world. Now it seems there is a strain that can not be treated by the commonly used prescription drugs.

TB strain identified as ‘virtually untreatable’

There are over 425,000 cases of multi-drug resistant (MRT) TB each years world-wide mostly in India, China and the former Soviet Union. The resistance develops primarily because treatment isn’t followed through completely.

Also, TB isn’t the only bacteria developing resistance. many common bacteria are now occurring that are resistant to many common anti-biotics and the number of drugs to treat these is not increasing at a equivalent pace.

The main problem is these drugs don’t generate huge financial numbers for big pharma and something is going to have to change before advances are made. Maybe once it again becomes a common problem like it was back in the early 20th century will there again be a resurgence in discovery activities related to antibiotics.

Other Resources

WHO | Tuberculosis
Center for Disease Control | Tuberculosis
MedlinePlus: Tuberculosis
Tuberculosis - Wikipedia, the free encyclopedia

Technorati Tags: , ,

Email Ed Vawter



Related Posts:
  • Major Pharma Layoffs
  • Price Pressures in Pharmaceuticals and Me Too Drugs.
  • Rising Diabetes Threat and Reduced Budget
  • Grassley, the FDA, and Ketek

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Potential New Drug for Prevention of Premature Births

    by @ 8:13 am.  Filed under FDA, Drug Development, Pharma

    Adeza has a new drug to help prevent premature births and is seen is a promising drug as reported by Forbes.

    Adeza Shares Seen As Attractive Following FDA News - Forbes.com:

    The article covers that the Reproductive Health Drugs Advisory Committee has recommended for approval Gestiva indicated to prevent premature births. Premature births occur much more frequently now than in past years mainly due to advancements made in fertility treatments; currently about 12% of all births are premature (less than 37 weeks gestation). Also, premature births tend to be very costly to the health care system. According to this site March of Dimes put the cost in 2003 of $11 billion for preterm birth.

    Further Resources

    Press Release from Adeza on FDA recommendation for approval
    Adezas Gestiva recommended for FDA approval - Pharmaceutical Business Review

    FDA questions effectiveness of Gestiva at preventing preterm labor

    Technorati Tags: , ,

    Email Ed Vawter



    Related Posts:
  • FDA Approves Second Drug for Preventing Influenza
  • Is Big Pharma Getting Desperate?
  • New Hopes for cheaper biogenerics?
  • Is the FDA Approving More Drugs?
  • Long-term Data Needed for Xenical, Meridia and Acomplia

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Pages (999999): [1] 2 3 » ... Last »

    [powered by WordPress.]

    QDIS: blogging about chemistry, drug development, science and technology.

    Internal Links

    Categories

    Search This Blog

    Archives

    September 2006
    S M T W T F S
    « Aug   Oct »
     12
    3456789
    10111213141516
    17181920212223
    24252627282930

    Search Entire Site

    Subscribe (It's Free!)

    Performancing

    Chemistry, science, and technology for the future.

    logo2

    General Links

    Blog Links

    Chemistry Journal Feeds

    Chemistry Feeds

    40 queries. 0.992 seconds